Concepedia

Publication | Closed Access

Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer

DOI

430

Citations

0

References

1993

Year

William K. Murphy, Frank V. Fossella, R Winn, Dong M. Shin, Harry E. Hynes, H. M. Gross, Enrique Davilla, J. T. Leimert, Hari M. Dhingra, M. N. Raber,
JNCI Journal of the National Cancer Institute

Abstract

A phase II study combining taxol, etoposide, and cisplatin and using hematopoietic stimulating factors is now proposed. The optimal dose for combination chemotherapy has yet to be determined. An important consideration is potential cardiac effects of taxol with other drugs.